{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:26:31Z","timestamp":1793305591230,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["40000747"],"award-info":[{"award-number":["40000747"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["40000747"],"award-info":[{"award-number":["40000747"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["40003419"],"award-info":[{"award-number":["40003419"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["33669945"],"award-info":[{"award-number":["33669945"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018225","name":"EuroNanoMed III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"Horizon 2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["887609"],"award-info":[{"award-number":["887609"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.biomaterials.2023.122006","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T05:31:31Z","timestamp":1674279091000},"page":"122006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival"],"prefix":"10.1016","volume":"294","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8973-4315","authenticated-orcid":false,"given":"Giuseppina","family":"Catania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rodella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Vanvarenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-1450","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Pr\u00e9at","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3694-8667","authenticated-orcid":false,"given":"Alessio","family":"Malfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2023.122006_bib1","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1039\/D1BM00896J","article-title":"Local delivery to malignant brain tumors: potential biomaterial-based therapeutic\/adjuvant strategies","volume":"9","author":"Alghamdi","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biomaterials.2023.122006_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/nop\/npac015","article-title":"Primary brain and other central nervous system tumors in the United States (2014-2018): a summary of the CBTRUS statistical report for clinicians","volume":"9","author":"Low","year":"2022","journal-title":"Neuro-Oncology Practice"},{"key":"10.1016\/j.biomaterials.2023.122006_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.biomaterials.2023.122006_bib4","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.biomaterials.2023.122006_bib5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biomaterials.2023.122006_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-022-02251-2","article-title":"Immunotherapy for glioblastoma: the promise of combination strategies","volume":"41","author":"Bausart","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2023.122006_bib7","first-page":"201","article-title":"Immunotherapy for glioblastoma: on the sidelines or in the game?","volume":"24","author":"Reardon","year":"2017","journal-title":"Discov. Med."},{"key":"10.1016\/j.biomaterials.2023.122006_bib8","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/0008-5472.CAN-16-2310","article-title":"Cellular and molecular identity of tumor-associated macrophages in GlioblastomaIdentity and gene profile of glioblastoma TAM","volume":"77","author":"Chen","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2023.122006_bib9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/glia.21264","article-title":"The brain tumor microenvironment","volume":"60","author":"Charles","year":"2012","journal-title":"Glia"},{"key":"10.1016\/j.biomaterials.2023.122006_bib10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ni.3423","article-title":"Origin, fate and dynamics of macrophages at central nervous system interfaces","volume":"17","author":"Goldmann","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biomaterials.2023.122006_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nri.2017.125","article-title":"Microglia and macrophages in brain homeostasis and disease","volume":"18","author":"Li","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biomaterials.2023.122006_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/nan.12428","article-title":"Tumour\u2010associated microglia\/macrophages predict poor prognosis in high\u2010grade gliomas and correlate with an aggressive tumour subtype","volume":"44","author":"S\u00f8rensen","year":"2018","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.biomaterials.2023.122006_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3390\/cancers14051319","article-title":"Tumor-associated macrophages in gliomas\u2014basic insights and treatment opportunities","volume":"14","author":"Andersen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2023.122006_bib14","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2023.122006_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb2311","article-title":"Immunocytokines are a promising immunotherapeutic approach against glioblastoma","volume":"12","author":"Weiss","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2023.122006_bib16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/neuonc\/noab271","article-title":"Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase I trial","volume":"24","author":"Chiocca","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.biomaterials.2023.122006_bib17","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.3390\/ijms21082759","article-title":"Challenges to successful implementation of the immune checkpoint inhibitors for treatment of glioblastoma","volume":"21","author":"Sanders","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2023.122006_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.biomaterials.2023.122006_bib19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/pharmaceutics14061228","article-title":"The role of toll-like receptor agonists and their nanomedicines for tumor immunotherapy","volume":"14","author":"Huang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biomaterials.2023.122006_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2741\/934","article-title":"CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma","volume":"8","author":"Carpentier","year":"2003","journal-title":"Frontiers in Bioscience-Landmark"},{"key":"10.1016\/j.biomaterials.2023.122006_bib21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ijc.21131","article-title":"Successful combination of local CpG\u2010ODN and radiotherapy in malignant glioma","volume":"116","author":"Meng","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biomaterials.2023.122006_bib22","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1158\/1078-0432.CCR-09-3087","article-title":"Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG TherapyGlioma CpG therapy","volume":"16","author":"Alizadeh","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2023.122006_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11671-019-3032-9","article-title":"Potent anti-tumor immunostimulatory biocompatible nanohydrogel made from DNA","volume":"14","author":"Jiang","year":"2019","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.biomaterials.2023.122006_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2016.12.003","article-title":"Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma\u2014a phase II multicentric, randomised study","volume":"73","author":"Ursu","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biomaterials.2023.122006_bib25","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biomaterials.2023.122006_bib26","first-page":"3620","article-title":"Mechanisms of Taxol-induced cell death are concentration dependent","volume":"58","author":"Torres","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2023.122006_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.oraloncology.2019.06.016","article-title":"Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer","volume":"95","author":"Park","year":"2019","journal-title":"Oral Oncol."},{"key":"10.1016\/j.biomaterials.2023.122006_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41435-021-00161-5","article-title":"Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma","volume":"23","author":"Decraene","year":"2022","journal-title":"Gene Immun."},{"key":"10.1016\/j.biomaterials.2023.122006_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1703449","article-title":"Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology","volume":"9","author":"Vanmeerbeek","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.biomaterials.2023.122006_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2018.08.028","article-title":"Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biomaterials.2023.122006_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113951","article-title":"Rationally designed drug delivery systems for the local treatment of resected glioblastoma","author":"Bastiancich","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2023.122006_bib32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/pharmaceutics14051025","article-title":"Combination of DNA vaccine and immune checkpoint blockades improves the immune response in an orthotopic unresectable glioblastoma model","volume":"14","author":"Bausart","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biomaterials.2023.122006_bib33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in GlioblastomaDexamethasone limits anti\u2013PD-1 benefit for GBM","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2023.122006_bib34","series-title":"Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy","first-page":"2012","author":"Sengupta","year":"2012"},{"key":"10.1016\/j.biomaterials.2023.122006_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag2942","article-title":"Anti\u2013PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM","volume":"8","author":"Mathios","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2023.122006_bib36","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.ijpharm.2015.09.062","article-title":"Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma","volume":"495","author":"Lollo","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biomaterials.2023.122006_bib37","first-page":"1365","article-title":"High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme","volume":"13","author":"Kadiyala","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2023.122006_bib38","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1158\/1078-0432.CCR-10-2444","article-title":"Carbon nanotubes enhance CpG uptake and potentiate antiglioma ImmunityGlioma immunotherapy with carbon nanotubes","volume":"17","author":"Zhao","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2023.122006_bib39","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3390\/pharmaceutics12121165","article-title":"Doxorubicin-loaded PLGA nanoparticles for cancer therapy: molecular weight effect of PLGA in doxorubicin release for controlling immunogenic cell death","volume":"12","author":"Choi","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biomaterials.2023.122006_bib40","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1538-7445.AM2018-5218","article-title":"Boosting doxorubicin-induced immunogenic cell death by using tumor microenvironment modulating nanoparticles","volume":"78","author":"Amini","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2023.122006_bib41","first-page":"e1532","article-title":"Envisioning the future of polymer therapeutics for brain disorders","volume":"11","author":"Rodriguez\u2010Otormin","year":"2019","journal-title":"Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology"},{"key":"10.1016\/j.biomaterials.2023.122006_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202000285","article-title":"Highway to success\u2014developing advanced polymer therapeutics","volume":"4","author":"Ashford","year":"2021","journal-title":"Advanced Therapeutics"},{"key":"10.1016\/j.biomaterials.2023.122006_bib43","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1958","article-title":"Polymer conjugates as anticancer nanomedicines","volume":"6","author":"Duncan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biomaterials.2023.122006_bib44","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1016\/j.biomaterials.2013.03.065","article-title":"Hyaluronic acid (HA) presentation as a tool to modulate and control the receptor-mediated uptake of HA-coated nanoparticles","volume":"34","author":"Almalik","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2023.122006_bib45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/pharmaceutics14010124","article-title":"Design of bio-responsive hyaluronic acid\u2013doxorubicin conjugates for the local treatment of glioblastoma","volume":"14","author":"Malfanti","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biomaterials.2023.122006_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121302","article-title":"Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer","volume":"280","author":"Singh","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2023.122006_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202000116","article-title":"Hyaluronic acid conjugates of Vorinostat and Bexarotene for treatment of cutaneous malignancies","volume":"3","author":"Sallam","year":"2020","journal-title":"Advanced Therapeutics"},{"key":"10.1016\/j.biomaterials.2023.122006_bib48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1152\/physrev.00052.2009","article-title":"Hyaluronan as an immune regulator in human diseases","volume":"91","author":"Jiang","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biomaterials.2023.122006_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201601012","article-title":"The CD44\u2010mediated uptake of hyaluronic acid\u2010based carriers in macrophages","volume":"6","author":"Rios de la Rosa","year":"2017","journal-title":"Advanced healthcare materials"},{"key":"10.1016\/j.biomaterials.2023.122006_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2021.129192","article-title":"Doxorubicin\/CpG self-assembled nanoparticles prodrug and dendritic cells co-laden hydrogel for cancer chemo-assisted immunotherapy","volume":"416","author":"Yang","year":"2021","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.biomaterials.2023.122006_bib51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jconrel.2021.05.033","article-title":"A dual macrophage polarizer conjugate for synergistic melanoma therapy","volume":"335","author":"Sallam","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2023.122006_bib52","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4049\/jimmunol.173.2.1179","article-title":"TLR9 is localized in the endoplasmic reticulum prior to stimulation","volume":"173","author":"Leifer","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2023.122006_bib53","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1021\/acsami.0c20607","article-title":"Lipid-polyglutamate nanoparticle vaccine platform","volume":"13","author":"Van Lysebetten","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biomaterials.2023.122006_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-9-66","article-title":"Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers","volume":"9","author":"Wright","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biomaterials.2023.122006_bib55","doi-asserted-by":"crossref","first-page":"17205","DOI":"10.1016\/S0021-9258(19)77815-6","article-title":"Glutathione metabolism and its selective modification","volume":"263","author":"Meister","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biomaterials.2023.122006_bib56","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/glycob\/10.6.587","article-title":"Conformational behavior of hyaluronan in relation to its physical properties as probed by molecular modeling","volume":"10","author":"Haxaire","year":"2000","journal-title":"Glycobiology"},{"key":"10.1016\/j.biomaterials.2023.122006_bib57","doi-asserted-by":"crossref","DOI":"10.21037\/sci.2020.02.02","article-title":"CD44 expression in stem cells and niche microglia\/macrophages following ischemic stroke","volume":"7","author":"Sawada","year":"2020","journal-title":"Stem Cell Invest."},{"key":"10.1016\/j.biomaterials.2023.122006_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2023.122006_bib59","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1158\/1078-0432.CCR-18-1728","article-title":"Antibody-based delivery of TNF to the tumor neovasculature potentiates the therapeutic activity of a peptide anticancer VaccineTargeted TNF potentiates the efficacy of a peptide vaccine","volume":"25","author":"Probst","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2023.122006_bib60","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1038\/cddis.2013.562","article-title":"Interleukin-1\u03b2 promotes hypoxia-induced apoptosis of glioblastoma cells by inhibiting hypoxia-inducible factor-1 mediated adrenomedullin production","volume":"5","author":"Sun","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biomaterials.2023.122006_bib61","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","article-title":"CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor CellsCCL2 in Treg and MDSC trafficking to glioma","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2023.122006_bib62","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2023.122006_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-38127-9","article-title":"In-depth characterization of monocyte-derived macrophages using a mass cytometry-based phagocytosis assay","volume":"9","author":"Schulz","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biomaterials.2023.122006_bib64","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.4049\/jimmunol.1001965","article-title":"GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation","volume":"187","author":"Curran","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2023.122006_bib65","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/stem.188","article-title":"Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth","volume":"27","author":"Wang","year":"2009","journal-title":"Stem Cell."},{"key":"10.1016\/j.biomaterials.2023.122006_bib66","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fimmu.2015.00422","article-title":"DAMPs from cell death to new life","volume":"6","author":"V\u00e9n\u00e9reau","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2023.122006_bib67","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.3892\/etm.2017.4989","article-title":"Calreticulin is an effective immunologic adjuvant to tumor-associated antigens","volume":"14","author":"Wang","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.biomaterials.2023.122006_bib68","doi-asserted-by":"crossref","first-page":"403","DOI":"10.18632\/oncotarget.1719","article-title":"Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing","volume":"5","author":"Gameiro","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.biomaterials.2023.122006_bib69","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/ijms22010247","article-title":"Characterization and differentiation of the tumor microenvironment (TME) of orthotopic and subcutaneously grown head and neck squamous cell carcinoma (HNSCC) in immunocompetent mice","volume":"22","author":"Brand","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2023.122006_bib70","first-page":"1","article-title":"Comparative study of subcutaneous and orthotopic mouse models of prostate cancer: vascular perfusion, vasculature density, hypoxic burden and BB2r-Targeting Efficacy","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biomaterials.2023.122006_bib71","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4049\/jimmunol.177.2.1272","article-title":"Hyaluronan fragments act as an endogenous danger signal by engaging TLR2","volume":"177","author":"Scheibner","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2023.122006_bib72","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2176\/nmc.ra2013-0234","article-title":"Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials","volume":"53","author":"Mineharu","year":"2013","journal-title":"Neurol. Med.-Chir."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961223000145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961223000145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:23:50Z","timestamp":1778667830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961223000145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":72,"alternative-id":["S0142961223000145"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2023.122006","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2023.122006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122006"}}